147 related articles for article (PubMed ID: 35547745)
1. Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs.
Li K; Sun X; Zha R; Liu S; Feng Y; Sano T; Aryal UK; Sudo A; Li BY; Yokota H
Theranostics; 2022; 12(7):3084-3103. PubMed ID: 35547745
[No Abstract] [Full Text] [Related]
2. Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling.
Sun X; Li K; Hase M; Zha R; Feng Y; Li BY; Yokota H
Theranostics; 2022; 12(2):929-943. PubMed ID: 34976221
[No Abstract] [Full Text] [Related]
3. Generation of the tumor-suppressive secretome from tumor cells.
Liu S; Sun X; Li K; Zha R; Feng Y; Sano T; Dong C; Liu Y; Aryal UK; Sudo A; Li BY; Yokota H
Theranostics; 2021; 11(17):8517-8534. PubMed ID: 34373756
[No Abstract] [Full Text] [Related]
4. Preventing tumor progression to the bone by induced tumor-suppressing MSCs.
Sun X; Li K; Zha R; Liu S; Fan Y; Wu D; Hase M; Aryal UK; Lin CC; Li BY; Yokota H
Theranostics; 2021; 11(11):5143-5159. PubMed ID: 33859739
[No Abstract] [Full Text] [Related]
5. Proteomes from AMPK-inhibited peripheral blood mononuclear cells suppress the progression of breast cancer and bone metastasis.
Li K; Sun X; Minami K; Tamari K; Ogawa K; Li H; Ma H; Zhou M; Na S; Li BY; Yokota H
Theranostics; 2023; 13(4):1247-1263. PubMed ID: 36923539
[No Abstract] [Full Text] [Related]
6. Enhancing anti-tumor potential: low-intensity vibration suppresses osteosarcoma progression and augments MSCs' tumor-suppressive abilities.
Xiong X; Huo Q; Li K; Cui C; Chang C; Park C; Ku B; Hong CS; Lim H; Pandya PH; Saadatzadeh MR; Bijangi-Vishehsaraei K; Lin CC; Kacena MA; Pollok KE; Chen A; Liu J; Thompson WR; Li XL; Li BY; Yokota H
Theranostics; 2024; 14(4):1430-1449. PubMed ID: 38389836
[No Abstract] [Full Text] [Related]
7. Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes.
Li K; Sun X; Li H; Ma H; Zhou M; Minami K; Tamari K; Ogawa K; Pandya PH; Saadatzadeh MR; Kacena MA; Pollok KE; Li BY; Yokota H
Genes Dis; 2023 Jul; 10(4):1641-1656. PubMed ID: 37397541
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract][Full Text] [Related]
9. PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh9.
Sun X; Li K; Aryal UK; Li BY; Yokota H
Mol Ther Oncolytics; 2022 Sep; 26():360-371. PubMed ID: 36090473
[TBL] [Abstract][Full Text] [Related]
10. Conversion of Osteoclasts into Bone-Protective, Tumor-Suppressing Cells.
Li KX; Sun X; Li BY; Yokota H
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830748
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Growth of Breast Cancer-Associated Brain Tumors by the Osteocyte-Derived Conditioned Medium.
Sano T; Sun X; Feng Y; Liu S; Hase M; Fan Y; Zha R; Wu D; Aryal UK; Li BY; Sudo A; Yokota H
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802279
[TBL] [Abstract][Full Text] [Related]
12. Correlation of micro vessel density and c-Myc expression in breast tumor of mice following mesenchymal stem cell therapy.
Adelipour M; Babaei F; Mirzababaei M; Allameh A
Tissue Cell; 2017 Apr; 49(2 Pt B):315-322. PubMed ID: 28209368
[TBL] [Abstract][Full Text] [Related]
13. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
14. The Pinx1 Gene Downregulates Telomerase and Inhibits Proliferation of CD133+ Cancer Stem Cells Isolated from a Nasopharyngeal Carcinoma Cell Line by Regulating Trfs and Mad1/C-Myc/p53 Pathways.
Shen C; Chen F; Wang H; Li G; Yu C; Wang X; Wen Z
Cell Physiol Biochem; 2018; 49(1):282-294. PubMed ID: 30138944
[TBL] [Abstract][Full Text] [Related]
15. Effect of overexpression of Oct4 and Sox2 genes on the biological and oncological characteristics of gastric cancer cells.
Chen B; Zhu Z; Li L; Ye W; Zeng J; Gao J; Wang S; Zhang L; Huang Z
Onco Targets Ther; 2019; 12():4667-4682. PubMed ID: 31417271
[No Abstract] [Full Text] [Related]
16. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
[TBL] [Abstract][Full Text] [Related]
17. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.
Corominas-Faja B; Cufí S; Oliveras-Ferraros C; Cuyàs E; López-Bonet E; Lupu R; Alarcón T; Vellon L; Iglesias JM; Leis O; Martín ÁG; Vazquez-Martin A; Menendez JA
Cell Cycle; 2013 Sep; 12(18):3109-24. PubMed ID: 23974095
[TBL] [Abstract][Full Text] [Related]
18. Bax regulates c-Myc-induced mammary tumour apoptosis but not proliferation in MMTV-c-myc transgenic mice.
Jamerson MH; Johnson MD; Korsmeyer SJ; Furth PA; Dickson RB
Br J Cancer; 2004 Oct; 91(7):1372-9. PubMed ID: 15354213
[TBL] [Abstract][Full Text] [Related]
19. Breast tumour cell subpopulations with expression of the MYC and OCT4 proteins.
Litviakov NV; Bychkov VA; Stakheeva MN; Ibragimova MK; Tsyganov MM; Gaptulbarova KA; Tashireva LA; Bondar LN; Garbukov EY; Slonimskaya EM
J Mol Histol; 2020 Dec; 51(6):717-728. PubMed ID: 33037978
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
Marino S; Bishop RT; Mollat P; Idris AI
Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
